RABIOPRED PROJECT We are taking the final steps for you.
RABIOPRED PROJECT         We are taking             the final steps                    for you.       

Rabiopred Project & Consortium at a glance

The RABIOPRED consortium is coordinated by Tc Land Expression S.A., a French SME developing biomarkers for personalized medicine and companion diagnostics in immune mediated disorders. For more information on Tc Land, please visit

www.tcland-expression.com

 

Firalis S.A.S. is a project partner and the parent company of Tc Land. Firalis is a leader SME in biomarker R&D, developing innovative diagnostic solutions in particular for cardiovascular desease and toxicities. For more information on Firalis, please visit www.firalis.com

 

The Project has officialy started on the 01 July 2015 and is funded fully for all costs to be generated within 42 months of its duration.

 

RABIOPRED Consortium will realize a "Prospective observational multicenter confirmatory Proof-of-Performance (PoP) clinical trial", within years 2 and 3 of the project, in participation of 5 highly prestigious clinical research centers:

  • Leiden Clinical Center (Prof. Tom Huizinga)
  • Montpellier Clinical Center (Prof. Christian Jorgensen)
  • Prague Clinical Center (Prof. Jiri Vencovský)
  • Strasbourg Clinical Center (Prof. Jacques-Eric Gottenberg)
  • Tel-Aviv Sauraski Clinical Center (Prof. Nadir Arber)

 

More information on these clinical centers will be available soon on this page. Until then, do not hesitate to contact us for your questions.

RABIOPRED is funded by HORIZON 2020
Research & Innovation Programme of EU
under the Grant Agreement No: 666798

Project Details

Acronym: RABIOPRED

Reference: 666798

Duration: 42 months

Topic: PHC-12-2014

Funding: 5 Mio EUR

Version imprimable Version imprimable | Plan du site
© RABIOPRED THE PROJECT